FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:2045-2048 November 11, 2004 Number 20 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Mannon, P. J. PubMed Citation

Crohn's disease is one of two idiopathic inflammatory bowel diseases that affect approximately 1 million people in North America. Despite important advances in diagnosis and treatment in recent years, the underlying cause of the disease remains unclear. As a result, the available therapies are not curative and may pose a substantial risk of side effects. A current theory regarding the pathogenesis of Crohn's disease suggests that there is an overly aggressive immune response against commensal bacteria in a genetically predisposed person. In this context, the activation of lymphocytes and the overexpression of inflammatory cytokines represent a common effector mechanism leading . . . [Full Text of this Article]

Source Information

From the Health Sciences Center, University of Virginia, Charlottesville.

This article has been cited by other articles:

• Sandborn, W. J., Feagan, B. G., Stoinov, S., Honiball, P. J., Rutgeerts, P., Mason, D., Bloomfield, R., Schreiber, S., the PRECISE 1 Study Investigators, (2007). Certolizumab Pegol for the Treatment of Crohn's Disease. NEJM 357: 228-238 [Abstract] [Full Text]  
• Amin, Md. R., Dudeja, P. K., Ramaswamy, K., Malakooti, J. (2007). Involvement of Sp1 and Sp3 in differential regulation of human NHE3 promoter activity by sodium butyrate and IFN-{gamma}/TNF-{alpha}. Am. J. Physiol. Gastrointest. Liver Physiol. 293: G374-G382 [Abstract] [Full Text]  
• Pizarro, T. T., Cominelli, F. (2007). Cloning IL-1 and the Birth of a New Era in Cytokine Biology. J. Immunol. 178: 5411-5412 [Full Text]  
• Amin, Md. R., Malakooti, J., Sandoval, R., Dudeja, P. K., Ramaswamy, K. (2006). IFN-{gamma} and TNF-{alpha} regulate human NHE3 gene expression by modulating the Sp family transcription factors in human intestinal epithelial cell line C2BBe1. Am. J. Physiol. Cell Physiol. 291: C887-C896 [Abstract] [Full Text]  
• Pizarro, T T, De La Rue, S A, Cominelli, F (2006). Role of interleukin 6 in a murine model of Crohn's ileitis: are cytokine/anticytokine strategies the future for IBD therapies?. Gut 55: 1226-1227 [Full Text]  
• Danese, S., Sans, M., Scaldaferri, F., Sgambato, A., Rutella, S., Cittadini, A., Pique, J. M., Panes, J., Katz, J. A., Gasbarrini, A., Fiocchi, C. (2006). TNF-{alpha} Blockade Down-Regulates the CD40/CD40L Pathway in the Mucosal Microcirculation: A Novel Anti-Inflammatory Mechanism of Infliximab in Crohn's Disease. J. Immunol. 176: 2617-2624 [Abstract] [Full Text]  
• Bamias, G., Nyce, M. R., De La Rue, S. A., Cominelli, F. (2005). New Concepts in the Pathophysiology of Inflammatory Bowel Disease. ANN INTERN MED 143: 895-904 [Full Text]  
• Griffiths, A. M. (2005). Enteral Nutrition in the Management of Crohn's Disease. JPEN J Parenter Enteral Nutr 29: S108-S117 [Abstract] [Full Text]  
• MacDonald, T. T., DiSabatino, A., Gordon, J. N. (2005). Immunopathogenesis of Crohn's Disease. JPEN J Parenter Enteral Nutr 29: S118-S125 [Abstract] [Full Text]